Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid Tumors

A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 DOSING SCHEDULES OF PF-00299804 IN PATIENTS WITH ADVANCED MALIGNANT SOLID TUMORS

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00225121

Enrollment

121

Registered

2005-09-23

Start date

2005-10-11

Completion date

2010-09-23

Last updated

2018-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms

Brief summary

The primary purpose of this study is to study the side effects of PF-00299804 and determine the highest dose that can be safely administered in patients with advanced cancer.

Interventions

DRUGPF-00299804

investigational drug by oral route (escalating doses depending on safety) administered until progression

Study design

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* Malignant solid tumor for which there is no currently approved treatment * Adequate bone marrow, liver, cardiac, and kidney function

Exclusion criteria

* Cardiac disease * Anticancer therapy within 4-6 weeks (depending on therapy) * Pregnant or breast-feeding

Design outcomes

Primary

Measure	Time frame
Safety	6 months

Secondary

Measure	Time frame
Pharmacokinetics	6 months
Pharmacodynamics	6 months
Efficacy	6 months

Countries

Netherlands, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026